PlasmaTech Biopharmaceuticals is a biopharmaceutical company that develops protein biologic therapies and oncology supportive care products. The company’s products are MuGard, for the management of oral mucositis; and ProctiGard for the treatment of radiation proctitis, a frequent side effect of radiation treatment to the pelvic region. It also develops CobaCyte, a mediated targeted delivery technology that has application in in tumor targeting. For more information, visit the company’s website at www.plasmatechbio.com